20/20 BioResponse is a business unit of 20/20 Genesystems, Inc., a leader in medical diagnostics and biological testing since 2003. Developers of BioCheckTM 20/20 operates a CLIA certified laboratory located in Rockville Maryland and manufactures BioCheck test kits, a field diagnostic test used by hundreds of emergency response and biodetection teams worldwide.
Investment opportunities are currently available to accredited investors, family offices, private equity and venture capital firms. 20/20 GeneSystems is strongly focused on bringing its technology to Asian markets in 2016 and 2017. We welcome inquiries from investment funds focusing on biotechnology and diagnostic products with an Asian market component.